Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18672391 | 0.85 | UHRF1 (0.42) | UHRF1HDAC4LMNADYRK1AKCNQ2 | |
| SCHEMBL25474417 | 0.82 | UHRF1 (0.43) | UHRF1HDAC4DYRK1AKCNQ2PSEN1 | |
| SCHEMBL18794707 | 0.82 | UHRF1 (0.43) | UHRF1HDAC4DYRK1AKCNQ2PSEN1 | |
| SCHEMBL6560416 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GAAHPGDUSP2PKM | |
| SCHEMBL12299268 | 0.82 | UHRF1 (0.46) | UHRF1HDAC4HDAC8DYRK1AKCNQ2 | |
| SCHEMBL22298879 | 0.80 | UHRF1 (0.38) | UHRF1HPGDPSEN1PSEN2APH1B | |
| SCHEMBL18879378 | 0.79 | KDM4E (0.38) | UHRF1HPGDPSEN1PSEN2APH1B | |
| SCHEMBL30490644 | 0.79 | UHRF1 (0.52) | UHRF1ALDH1A1GAAHDAC4LMNA | |
| SCHEMBL84469 | 0.79 | UHRF1 (0.52) | UHRF1ALDH1A1GAAHDAC4LMNA | |
| SCHEMBL3465311 | 0.78 | UHRF1 (0.43) | UHRF1DYRK1APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3354650-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-4871848-A | OIL, GAS WELLS CORROSION INHIBITORS | THE DOW CHEMICAL COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| US-4740320-A | REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4725373-A | CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-02-16 | — | — | US | disclosed |
| US-4724003-A | Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines | THE DOW CHEMICAL COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4676834-A | Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone | THE DOW CHEMICAL COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | UHRF1 876/4885ALDH1A1 3839/4885GAA 15/4885 |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | UHRF1 4153/4885ALDH1A1 2952/4885GAA 2198/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | UHRF1 4153/4885ALDH1A1 2952/4885GAA 2198/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | UHRF1 2773/4885ALDH1A1 1814/4885GAA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.